ECIL-5建议：血液恶性肿瘤以及接受造血干细胞移植患者病毒性肝炎的管理.pdf

Review Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5) Vincent Mallet, Florian van Bömmel, Christopher Doerig, Sven Pischke, Olivier Hermine, Anna Locasciulli, Catherine Cordonnier, Thomas Berg, Darius Moradpour, Heiner Wedemeyer, Per Ljungman, on behalf of ECIL-5* Summary Lancet Infect Dis 2016; Viral hepatitis aff ects millions of people worldwide, and host immunity is the key determinant of patient outcome. 16: 606–17 Viral hepatitis can be life threatening in patients with haematological malignancy, including haemopoietic stem cell *Listed at end of report transplant recipients, because of the virus itself, or through a need to decrease the dose of chemotherapy. A past or Université Paris Descartes, currently infected haemopoietic stem cell donor could also transmit viral hepatitis. The burden of viral hepatitis in Sorbonne Paris Cité, Paris, France patients with haematological malignancies and the weak evidence on which previous guidelines are based has (Prof V Mallet MD); Institut Pasteur, Institut National de la prompted the European Conference on Infection in Leukaemia (ECIL-5) to convene a group of experts in the fi elds of Santé et de la Recherche viral hepatitis and of haematological malignancy to specifi cally address previously unconsidered issues and grade the Médicale Unité 1223, Paris, available quality of evidence according to the Infectious Diseases Society of America grading system. T